Lance Alstodt - Jan 9, 2023 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role: President, CEO, COB, Director
Signature: /s/ Lance Alstodt
Stock symbol: BRTX
Transactions as of: Jan 9, 2023
Transactions value $: $308
Form type: 4
Date filed: 1/10/2023, 05:06 PM
Previous filing: Dec 28, 2022
Next filing: Jan 20, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BRTX	Common Stock	Purchase	$308	+100	+0.05%	$3.08	186K	Jan 9, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	BRTX	Stock Option						293K	Jan 9, 2023	Common Stock	293K	$5.08	Direct	F2
holding	BRTX	Stock Option						42.1K	Jan 9, 2023	Common Stock	42.1K	$5.08	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 100,935 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,036 shares on January 18, 2023, 1,037 shares on February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024.
F2	The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 with the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
F3	The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.